Skip to main
ARVN
ARVN logo

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 32%
Sell 0%
Strong Sell 5%

Bulls say

Arvinas Inc is focused on developing therapies that target and degrade disease-causing proteins, leveraging its proprietary PROTAC technology, which has shown a significant safety advantage in comparative trials, as indicated by an observed 7% increase in AST among patients treated with ASP3082. The company's candidate ARV-806 demonstrated superior potency in preclinical models, reducing KRAS G12D protein levels over 40 times more effectively than existing clinical degraders, indicating a meaningful pharmacologic advantage that may enhance both efficacy and safety in targeted treatments for KRAS G12D mutant tumors. Furthermore, the promising results from ARV-806's synergistic effects with PD-1 blockade suggest that Arvinas's innovative approaches could lead to improved immunotherapy outcomes, enhancing the company's potential for successful commercialization and patient impact.

Bears say

The analysis indicates a negative outlook for Arvinas Inc, primarily due to concerns regarding revenue expectations and capital access. The projected peak revenue for vepdeg has been significantly reduced from $641.2 million to $296.9 million, reflecting less favorable market conditions and anticipated difficulty in market penetration. Additionally, the company faces potential challenges stemming from a declining response rate for its therapies, which, coupled with limitations in capital access, may hinder critical operations and delay the path to profitability.

Arvinas Inc (ARVN) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 32% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 19 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.